Rajesh Dave, MD
Cardiovascular Disease · Camp Hill, PANPI 1184627333
Payments from drug & device makers
Across 1,181 payments — averaging $581.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$160K
- Merck$93K
- Amgen$79K
- American Regent$54K
- Chiesi USA, Inc.$53K
- Trireme Medical LLC$51K
- plus $196K from 54 others
Across 7 payments — averaging $3028.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Microvention, Inc.$15K
- Philips North America LLC$4K
- Cook Research Incorporated$2K
What the payments were for
- Consulting fees$105,92024%
- Speaking & faculty fees$260,44659%
- Travel & lodging$41,7909%
- Food & beverage$25,6496%
- Education$100%
- Other$8,1812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$151,591
- Xience V coronary stent system$67,150
- KENGREAL$52,883
- Repatha$46,606
- NEXLIZET$43,816
- NEXLETOL$43,816
- FARXIGA$27,354
- PRALUENT$25,722
- LEXISCAN$17,935
- Ozempic$11,377
- Auryon Laser System 100-120 Vac$8,181
- Coronary Orbital Atherectomy System$7,766
- Peripheral Orbital Atherectomy System$7,766
- Vascepa$7,633
- JETi Peripheral Catheter$5,400
- Mitra Clip system$1,888
- KENGREAL 50MG/10ML L$500
- ENDOCROSS Device$452
- Torus Stent Graft System$452
- OPTIS$332
How this compares
$686,357 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 223 | $268,508 |
| EliquisApixaban | 206 | $254,637 |
| XareltoRivaroxaban | 113 | $116,621 |
| OzempicSemaglutide | 61 | $70,381 |
| Repatha SureclickEvolocumab | 57 | $57,655 |
| JardianceEmpagliflozin | 37 | $43,827 |
| Repatha SyringeEvolocumab | 44 | $32,267 |
| Praluent PenAlirocumab | 40 | $30,382 |
| FarxigaDapagliflozin Propanediol | 24 | $27,048 |
| VerquvoVericiguat | 34 | $26,968 |
| BrilintaTicagrelor | 17 | $17,084 |
| Ranolazine ErRanolazine | 200 | $15,987 |
| VascepaIcosapent Ethyl | 13 | $10,897 |
| ClopidogrelClopidogrel Bisulfate | 414 | $6,851 |
| Metoprolol Succinate | 281 | $4,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,479 | $268,508223 claims |
| PfizerEliquis | $622 | $254,637206 claims |
| Johnson & JohnsonXarelto | $866 | $116,621113 claims |
| Novo NordiskOzempic | $11,827 | $70,38161 claims |
| AstraZenecaFarxiga, Brilinta | $28,905 | $44,13241 claims |
| Boehringer IngelheimJardiance | $859 | $43,82737 claims |
| MerckVerquvo | $93,111 | $26,96834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Camp Hill
- Venkatesh NadarCamp Hill$18.3M
- Danielle DuffyPhiladelphia$29.5M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
- Paul GrenaYardley$1.6M
- Peter KoweyWynnewood$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.